Tulobuterol

This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.

Identification

Summary

Tulobuterol is an inhaled long-acting beta2-adrenergic receptor agonist used as a bronchodilator in the management of asthma and COPD.

Generic Name
Tulobuterol
DrugBank Accession Number
DB12248
Background

Tulobuterol has been used in trials studying the treatment of Chronic Obstructive Pulmonary Disease.

Type
Small Molecule
Groups
Investigational
Structure
Thumb
Weight
Average: 227.73
Monoisotopic: 227.1076919
Chemical Formula
C12H18ClNO
Synonyms
  • Tulobuterol

Pharmacology

Indication

Not Available

Pharmacology
Accelerate your drug discovery research with the industry’s only fully connected ADMET dataset, ideal for:
Machine Learning
Data Science
Drug Discovery
Accelerate your drug discovery research with our fully connected ADMET dataset
Learn more
Associated Conditions
Contraindications & Blackbox Warnings
Contraindications
Contraindications & Blackbox Warnings
With our commercial data, access important information on dangerous risks, contraindications, and adverse effects.
Learn more
Our Blackbox Warnings cover Risks, Contraindications, and Adverse Effects
Learn more
Pharmacodynamics

Not Available

Mechanism of action
TargetActionsOrganism
UBeta-2 adrenergic receptorNot AvailableHumans
Absorption

Not Available

Volume of distribution

Not Available

Protein binding

Not Available

Metabolism
Not Available
Route of elimination

Not Available

Half-life

Not Available

Clearance

Not Available

Adverse Effects
Medicalerrors
Reduce medical errors
and improve treatment outcomes with our comprehensive & structured data on drug adverse effects.
Learn more
Reduce medical errors & improve treatment outcomes with our adverse effects data
Learn more
Toxicity

Not Available

Pathways
Not Available
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
DrugInteraction
AcebutololThe therapeutic efficacy of Tulobuterol can be decreased when used in combination with Acebutolol.
AceclofenacThe risk or severity of hypertension can be increased when Aceclofenac is combined with Tulobuterol.
AcemetacinThe risk or severity of hypertension can be increased when Tulobuterol is combined with Acemetacin.
Acetylsalicylic acidThe risk or severity of hypertension can be increased when Acetylsalicylic acid is combined with Tulobuterol.
AclidiniumThe risk or severity of Tachycardia can be increased when Aclidinium is combined with Tulobuterol.
AdenosineThe risk or severity of Tachycardia can be increased when Adenosine is combined with Tulobuterol.
AlclofenacThe risk or severity of hypertension can be increased when Tulobuterol is combined with Alclofenac.
AlfentanilThe risk or severity of hypertension can be increased when Alfentanil is combined with Tulobuterol.
AlfuzosinThe therapeutic efficacy of Tulobuterol can be decreased when used in combination with Alfuzosin.
AliskirenTulobuterol may decrease the antihypertensive activities of Aliskiren.
Interactions
Improve patient outcomes
Build effective decision support tools with the industry’s most comprehensive drug-drug interaction checker.
Learn more
Food Interactions
Not Available

Products

Products
Comprehensive & structured drug product info
From application numbers to product codes, connect different identifiers through our commercial datasets.
Learn more
Easily connect various identifiers back to our datasets
Learn more
Product Ingredients
IngredientUNIICASInChI Key
Tulobuterol HydrochlorideVNC12181T056776-01-3RSLNRVYIRDVHLY-UHFFFAOYSA-N

Categories

ATC Codes
R03CC11 — TulobuterolR03AC11 — Tulobuterol
Drug Categories
Chemical TaxonomyProvided by Classyfire
Description
This compound belongs to the class of organic compounds known as chlorobenzenes. These are compounds containing one or more chlorine atoms attached to a benzene moiety.
Kingdom
Organic compounds
Super Class
Benzenoids
Class
Benzene and substituted derivatives
Sub Class
Halobenzenes
Direct Parent
Chlorobenzenes
Alternative Parents
Aralkylamines / Aryl chlorides / Secondary alcohols / 1,2-aminoalcohols / Dialkylamines / Organopnictogen compounds / Organochlorides / Hydrocarbon derivatives / Aromatic alcohols
Substituents
1,2-aminoalcohol / Alcohol / Amine / Aralkylamine / Aromatic alcohol / Aromatic homomonocyclic compound / Aryl chloride / Aryl halide / Chlorobenzene / Hydrocarbon derivative
Molecular Framework
Aromatic homomonocyclic compounds
External Descriptors
Not Available
Affected organisms
Not Available

Chemical Identifiers

UNII
591I9SU0F7
CAS number
41570-61-0
InChI Key
YREYLAVBNPACJM-UHFFFAOYSA-N
InChI
InChI=1S/C12H18ClNO/c1-12(2,3)14-8-11(15)9-6-4-5-7-10(9)13/h4-7,11,14-15H,8H2,1-3H3
IUPAC Name
2-(tert-butylamino)-1-(2-chlorophenyl)ethan-1-ol
SMILES
CC(C)(C)NCC(O)C1=CC=CC=C1Cl

References

General References
  1. TITCK Product Information: Tulair (tulobuterol hydrochloride) oral syrup [Link]
PubChem Compound
5606
PubChem Substance
347828525
ChemSpider
5404
BindingDB
50421717
RxNav
38967
ChEBI
93856
ChEMBL
CHEMBL1159717
Wikipedia
Tulobuterol

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
4CompletedTreatmentAsthma / Bronchial Asthma1
4Unknown StatusTreatmentChronic Obstructive Pulmonary Disease (COPD)1
Not AvailableRecruitingPreventionTonsillar Hypertrophy1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
Not Available
Dosage Forms
FormRouteStrength
SyrupOral
Tablet
SyrupOral1 mg/5ml
SyrupOral20 mg
Prices
Not Available
Patents
Not Available

Properties

State
Not Available
Experimental Properties
Not Available
Predicted Properties
PropertyValueSource
Water Solubility0.366 mg/mLALOGPS
logP2.95ALOGPS
logP2.56ChemAxon
logS-2.8ALOGPS
pKa (Strongest Acidic)13.9ChemAxon
pKa (Strongest Basic)9.55ChemAxon
Physiological Charge1ChemAxon
Hydrogen Acceptor Count2ChemAxon
Hydrogen Donor Count2ChemAxon
Polar Surface Area32.26 Å2ChemAxon
Rotatable Bond Count4ChemAxon
Refractivity63.88 m3·mol-1ChemAxon
Polarizability24.53 Å3ChemAxon
Number of Rings1ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET Features
Not Available

Spectra

Mass Spec (NIST)
Not Available
Spectra
SpectrumSpectrum TypeSplash Key
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available

Targets

Drugtargets
Accelerate your drug discovery research
with our fully connected ADMET & drug target dataset.
Learn more
Accelerate your drug discovery research with our ADMET & drug target dataset
Learn more
Kind
Protein
Organism
Humans
Pharmacological action
Unknown
General Function
Protein homodimerization activity
Specific Function
Beta-adrenergic receptors mediate the catecholamine-induced activation of adenylate cyclase through the action of G proteins. The beta-2-adrenergic receptor binds epinephrine with an approximately ...
Gene Name
ADRB2
Uniprot ID
P07550
Uniprot Name
Beta-2 adrenergic receptor
Molecular Weight
46458.32 Da
References
  1. Burioka N, Takata M, Endo M, Miyata M, Takeda K, Chikumi H, Tomita K, Fukuoka Y, Nakazaki H, Sano H, Shimizu E: Treatment with beta2-adrenoceptor agonist in vivo induces human clock gene, Per1, mRNA expression in peripheral blood. Chronobiol Int. 2007;24(1):183-9. [Article]
  2. Zhao XF, Huang JJ, Li Q, Wei LS, Zheng JB, Zheng XH, Li ZJ, Zhang YY: Revealing binding interaction between seven drugs and immobilized beta2-adrenoceptor by high-performance affinity chromatography using frontal analysis. J Mol Recognit. 2013 May;26(5):252-7. doi: 10.1002/jmr.2271. [Article]

Drug created on October 20, 2016 21:43 / Updated on May 27, 2021 02:57